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Abstract: Numerous inflammatory and innate immune pathways are involved in atherogenesis. Elaboration of clinical 
models of inflammation-induced atherogenesis may further advance our knowledge of multiple inflammatory pathways 
implicated in atherogenesis and provide a useful tool for cardiovascular prevention. Familial Mediterranean fever (FMF) 
is a chronic inflammatory disorder with profiles of inflammatory markers close to that seen in the general population. In a 
few recent studies, it has been shown that endothelial dysfunction, increased atherosclerotic burden and activation of 
platelets accompany attack-free periods of FMF. Colchicine is proved to be useful in suppression of inflammation in 
FMF.  Preliminary  basic  and  clinical  studies  suggest  that  this  relatively  safe  drug  may  be  useful  for  cardiovascular  
protection in patients with FMF and in the general population. Multinational prospective studies are warranted to further 
elaborate clinical model of inflammation-induced atherosclerosis associated with FMF.  
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INTRODUCTION 
  Atherosclerosis  is  the  main  contributor  to  the  global 
morbidity and mortality [1]. It starts early in life, progresses 
slowly and asymptomatically with aging, eventually result-
ing in atherosclerotic cardiovascular disease, adverse vascu-
lar events and death. Staggering amount of evidence derived 
from experimental and clinical studies suggests that multiple 
immune and inflammatory agents orchestrate atherosclerotic 
vasculopathy throughout the whole course of atherogenesis 
[2,3]. 
  Initial stages of atherosclerotic vasculopathy are charac-
terized by disruption of the integrity of endothelial mono-
layer, exposure of the constituents of subendothelial space to 
the  blood  flow,  recruitment  of  immune  and  inflammatory 
cells into the vascular wall, vascular inflammation and dec- 
reased production of vasoprotective agents [4, 5]. An interac-
tion of endothelial cells with T- and B-lymphocytes, neut- 
rophils, platelets and numerous  immune  and inflammatory 
agents produced by these cells leads toward atherosclerotic 
plaque formation, its destabilization and rupture [6-9]. 
  Over  the  past  decade,  it  has  become  evident  that  up-
regulation  of  inflammation  and  autoimmune  aggression  in 
certain systemic disorders such as systemic lupus erythema-
tosus (SLE) and rheumatoid arthritis (RA) may substantially 
accelerate  atherogenesis  and  increase  the  risk  of  vascular 
events  [10-12].  Basic  and  clinical  research  studies  in  this 
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field  have  led  to  the  emergence  of  a  new  biomedical  
discipline, vascular rheumatology [13], which aims to clarify 
pathophysiology  of  rheumatic  diseases  and  co-morbidities 
and to propose recommendations for primary and secondary 
prevention  of  vascular  events  in  the  general  population. 
Clinical  models  of  inflammation-induced  atherosclerosis 
elaborated  over  the  past  decade  are  mainly  based  on  the  
cardiovascular phenomenon described within the frames of 
high-grade inflammatory conditions. Much less attention has 
been paid to atherogenesis in low-grade inflammatory condi-
tions, such as psoriatic arthritis [14, 15], ankylosing spondy-
litis [16] and familial  Mediterranean fever (FMF) [17, 18] 
which manifest with inflammatory profiles close to that seen 
in  the  general  population.  Better  understanding  of  diverse 
inflammatory  pathways  associated  with  atherogenesis  may 
provide useful tools for cardiovascular prevention with drugs 
proved  their  efficiency  in  these  disorders  (for  example,  
colchicine in FMF).  
  The aim of the current mini-review  is to discuss latest 
data supporting the concept of FMF as a clinical model of 
atherogenesis associated with low-grade inflammation. 
FMF  AS  A  LOW-GRADE  INFLAMMATORY  
DISORDER 
  FMF has been classified as a systemic autoinflammatory 
disorder characterized by seemingly unprovoked activation 
of diverse inflammatory pathways [19, 20]. It is an ancient 
disease with wide-spread distribution in the Eastern Mediter-
ranean region and sporadic occurrence throughout the world. 
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However, it is largely recognized as an autosomal recessive 
trait  associated with  missense mutations in  the  MEditerra-
nean FeVer (MEFV) gene located on the short arm of chro-
mosome  16  [21].  The  gene  is  predominantly  expressed  in 
neutrophils [22]. The mutant pyrin protein encoded by the 
MEFV gene contains 781 amino acids and 4 domains (pyrin 
N-terminal, B-BOX type zinc finger, Coiled Coil and B30.2 
C-terminal).  The  B30.2  domain  encoded  by  the  last,  10
th 
exon of the MEFV gene which is the location of all severe 
mutations (M694V,  M694I,  M680I) [21].  These  mutations 
are responsible for dysregulation of apoptosis and inflamma-
tion due to the reduced ability of the mutated pyrin protein to 
modulate  activity  of  inflammasome  and  interleukin-1beta 
(IL-1beta)  [19].  Importantly,  the  same  mutations  were  
found responsible for subclinical inflammation in apparently 
healthy subjects [23, 24] and were associated with myocar-
dial  infarction  (MI)  in  the  general  population  [25],  severe  
course of inflammation with arthritis in inflammatory bowel 
disease [26], vascular involvement in Behçet’s disease (BD) 
[27]. 
  The hallmark of FMF is a self-limiting febrile attack of 
polyserositis followed by attack-free period. In a large pro-
portion of patients symptom-free intervals of the disease are 
characterized by subclinical inflammation with overproduc-
tion of C-reactive protein (CRP), serum amyloid A (SAA) 
and other acute-phase reactants [28,29]. During attack-free 
periods,  patients  with  FMF  may  still  experience  arthritis, 
myalgia, autonomic dysregulation with altered cardiovascu-
lar reactivity [30] and other cardiovascular symptoms related 
to  persistent  subclinical  inflammation  [18].  Importantly,  
recent  studies  with  cardiovascular  imaging  techniques  
identified signs of diastolic dysfunction  and microvascular 
coronary  pathology  which  were  correlated  with  elevated 
levels  of  CRP  during  attack-free  period  [31,  32].  Clinical 
significance  of  coronary  pathology  in  FMF  was  also  
highlighted in a few previous reports of coronary vasculitis, 
transient  left  bundle  branch  block  and  MI  associated  with 
inflammation in FMF [33-35].  
  Persistent  inflammation  in  FMF  may  cause  endothelial 
dysfunction, atherothrombosis and systemic amyloidosis, all 
of which share some genetic,  immunological  and morpho-
logical  features  [36].  Systemic  amyloidosis  is  the  most 
dreadful  manifestation  of  the  disease  which  define  its  
outcome [37, 38].  Rarely, amyloidosis  in  FMF  affects the 
myocardium and coronary vessels [39-41].  
ENDOTHELIAL DYSFUNCTION IN FMF 
  Endothelial cells play a crucial role in the migration of 
activated  neutrophils  into  the  subendothelial  space  and  in  
the initiation of the vessel wall inflammation [42]. Endothe-
lial  adhesion  molecules,  such  as  intercellular  adhesion  
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 
(VCAM-1),  facilitate  cellular  interactions  between  neutro-
phils,  T-  and  B-lymphocytes,  monocytes/macrophages,  
endothelial cells, whereas neutrophils, as an abundant source 
of  oxygen  reactive  species  and  proteolytic  enzymes,  act 
against endothelial cell junctions, thus opening route toward 
vascular smooth muscle cell [43]. This basic mechanism of 
endothelial  dysfunction  initiated  by  neutrophils  underlies 
diverse disorders associated with inflammation [44, 45] and 
may play even more active role in FMF. 
  Though vasculopathic cellular and molecular agents are 
not fully explored within the frames of FMF, neutrophils are 
believed  to  be  the  main  inflammatory  cells  implicated  in 
endothelial dysfunction, oxidative stress and overproduction 
of adhesion molecules in this disorder [46]. Neutrophils of 
patients  with  FMF  may  remain  hyperactive  during  attack-
free period due to the sustained overproduction of interleu-
kins-17 (IL-17) and -18 (IL-18) [47]. Of note, IL-18 is one 
of  the  main  pro-inflammatory  cytokines,  exerting  its  pro-
atherogenic effects via inflammasome activation and release 
of adhesion molecules [48], secretion of interferon-gamma 
[49] and upregulation of other pro-inflammatory cytokines 
(e.g., interleukin-8 [IL-8]) [50]. 
  It  has  been  shown  that  attack-free  period  in  FMF  is  
characterized by ongoing endothelial damage with elevation 
of  circulating  markers  of  endothelial  dysfunction  such  as 
thrombomodulin  [51],  adrenomedullin  and  nitrite  [52].  
Elevated  CRP  [53]  and  vascular  endothelial  growth  factor 
[54,  55]  can  be  considered  as  direct  contributors  to  the  
vascular damage and endothelial dysfunction in FMF.  
PROTHROMBOTIC STATE IN FMF 
  Over the past few years, several reports have been pub-
lished, linking subclinical inflammation with markers of hy-
percoagulation and thrombosis in FMF [56-60]. As a result, 
it has become possible to formulate hypothesis which con-
siders FMF as a prothrombotic disorder [57]. Interestingly, 
implications of the MEFV gene in thrombosis have not been 
investigated in FMF, but its common mutations have been 
associated  with  the  susceptibility  to  venous  thrombosis  in 
BD [61]. 
  Hypercoagulation in attack-free period in FMF was charac- 
terized by shortened prothrombin time and  thrombin  time, 
decreased  protein  C  activity  and  elevation  of  prothrombin 
fragment F1+2 [56]. Besides, in one study, platelet activation 
was  documented  by  an  increase  of  the  size  of  circulating 
platelets during the same period in FMF [62]. However, in 
another  similar  study,  there  was  no  difference  in  platelet 
function  among  patients  with  FMF  and  healthy  controls 
which was interpreted as a positive (anti-platelet) effect of 
colchicine therapy [63].  
  It  should  be  emphasized  that  platelet  activation  is  an  
essential  link  between  inflammatory,  thrombotic  and  
atherogenic pathways [64]. Activated platelets interact with  
neutrophils  and  endothelial  cells  and  through  the  release  
of  P-selectin  and  other  pro-inflammatory  agents  facilitate  
participation of immune cells in vascular inflammation and 
atherogenesis [65]. 
  In this regard, further studies are warranted to investigate 
interaction of platelets with markers of inflammation derived 
from other cells (e.g., IL-8, neutrophilic enzymes, CRP) and 
to determine vascular predictive value of activated platelets 
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ATHEROSCLEROTIC BURDEN IN FMF 
  Surrogate markers of atherosclerosis, such as the carotid 
artery intima-media thickness (IMT) has emerged as an useful 
tool  for  assessment  of  the  burden  of  atherosclerosis  and  
efficiency of cardiovascular therapies [66]. In most studies, 
the observed association of circulating inflammatory markers 
with an increased carotid artery IMT in chronic inflammatory 
disorders led to a conclusion that these disorders are associ-
ated with accelerated atherosclerosis and heightened risk of 
atherothrombotic events [67]. 
  Atherosclerotic  burden  measured  by  the  carotid  artery 
IMT  was  also  assessed  in  patients  with  FMF  [17,  68-71]. 
Intima-media  thickening  was  associated  with  elevation  of 
SAA and fibrinogen during attack-free period [17]. None of 
the  studies  investigating  carotid  atherosclerosis  in  FMF 
found  an  increase  of  the  prevalence  of  atherosclerotic 
plaques which was seen in high-grade inflammatory disor-
ders (e.g., SLE, RA). The latter can be interpreted as a result 
of less aggressive course of atherosclerosis in FMF [71]. It 
is, however, possible to speculate that colchicine therapy was 
responsible for less aggressive course of atherogenesis in the 
most studies in FMF. Prospective studies with the patients 
examined  for  atherosclerotic  burden  at  baseline  (when  the 
diagnosis is made and colchicine administered) and at sev-
eral time-points of the long-term follow-up, most probably, 
will  ascertain  whether  colchicine  affects  the  course  of 
atherogenesis in FMF.  
COLCHICINE THERAPY AND ATHEROGENESIS 
  Colchicine  is  an  alkaloid  derived  from  the  plant  Col-
chicum autumnale. Extract of the plant has been successfully 
used for the treatment of gouty arthritis for centuries [72]. 
Also,  colchicine  has  been  demonstrated  effectiveness  in 
various inflammatory and (auto)immune disorders (e.g., liver 
cirrhosis, necrotizing vasculitis, BD, psoriasis, scleroderma, 
sarcoidosis,  thrombocytopenic  purpura,  pericarditis,  skin 
diseases with neutrophils infiltration) [72, 73]. However, the 
first report on successful treatment of attacks of FMF with 
colchicine  published  in  1972  [74]  and  large  clinical  trials 
[75, 76] distinguished colchicine as a drug of choice for pre-
vention  of  attacks  and  amyloidosis  in  FMF.  As  a  result, 
nowadays, regular colchicine intake at a dose of 1-2 mg/day 
is  considered as a relatively safe and  effective therapeutic 
option for the suppression of inflammation and prevention of 
inflammatory co-morbidities in FMF [77].  
  The  main  mechanism  of  action  of  colchicine,  favoring  
its use in FMF, is dependent on selective  accumulation in 
neutrophils,  disruption  of  polymerization  of  microtubules, 
and suppression of neutrophils chemotaxis [78]. Colchicine 
alters expression of the MEFV [79] and other genes regulat-
ing  inflammatory  pathways  [80]  exerts  anti-cytokinergic  
and fibrolytic  effects [81, 82] further expanding its use  in  
inflammatory disorders (most notably in recurrent pericardi-
tis [83]). 
  Preliminary  data  suggest  that  anti-inflammatory  profile 
of colchicine may have cardiovascular implications in FMF. 
In a 6-month colchicine trial, patients with FMF at preamy-
loidal  and  early  amyloidal  stages  demonstrated  significant 
improvement of diastolic function [84]. In another retrospec-
tive study with a large cohort of FMF patients (n=290) regu-
larly treated with colchicine the prevalence of ischemic heart 
disease  (IHD)  and  established  cardiovascular  risk  factors 
were comparable to that of healthy controls [85]. 
  Promising results of the studies on anti-inflammatory and 
cardioprotective effects of colchicine in FMF made it possi-
ble to investigate benefits of colchicine in patients with car-
diovascular  disease  with  elevated  levels  of  inflammatory 
markers. In particular, in a one-month study with 44 patients 
with stable IHD and elevated CRP (>2.0 mg/L), colchicine 
(1 mg/day) significantly lowered CRP without side effects 
[86]. Unfortunately, owing to the safety concerns, there are 
no  long-term  studies  which  could  clarify  whether  the  ob-
served effect on CRP has implications in terms of reducing 
vascular events. 
  Established  short-term  anti-inflammatory  effects  and 
safety profile of colchicine may however have implications 
for prevention of restenosis in patients undergoing percuta-
neous transluminal angioplasty. Although clinical evidence 
to support this hypothesis is non-existent (perhaps due to the 
safety  concerns),  one  recent  experimental  study  on  an-
gioplasty of iliofemoral arteries in dogs demonstrated safety 
and  dose-dependent  potential  of  colchicine  in  preventing 
intimal hyperplasia within 2 weeks of the drug therapy [87]. 
Importantly,  further  studies  in  different  animal  models  of 
angioplasty at coronary and other vascular sites with differ-
ent regimes of colchicine therapy (oral intake, local applica-
tion,  low,  moderate,  high  doses)  are  warranted  before  
clinical studies. 
CONCLUSIONS 
  Preliminary  studies  suggest  that  attack-free  periods  of 
FMF  are  characterized  by  subclinical  inflammation  and  
associated endothelial dysfunction, increased atherosclerotic 
burden  and  platelets  activation.  Colchicine  demonstrated 
relatively  safe  anti-inflammatory  potential  which  seems  
potentially  useful  for  amelioration  of  endothelial  function, 
suppression  of  prothrombotic  pathways  and  decrease  of  
atherosclerotic  burden  (Fig.  1).  The  effects  of  colchicine  
on  cardiovascular  morbidity  and  mortality  have  not  been 
studied  prospectively.  Nevertheless,  clinical  experience  on 
regular colchicine therapy accumulated over the past decades 
suggests that in populations of patients exposed to colchicine 
from  early  stages  of  the  disease  (e.g.,  the  patients  from  
Israel)  the  prevalence  of  IHD  is  not  higher  than  that  in  
the general population [85]. Moreover, in most previous ret-
rospective studies, those on regular colchicine therapy were 
free  of  established  cardiovascular  risk  factors,  such  as 
dyslipidemia  and  hypertension.  Given  the  differences  in 
clinical  manifestations,  cardiovascular  risk  profiles  and  
responsiveness to colchicine in populations of FMF patients 
from  different  countries,  multinational  prospective  studies 
with  emphasis  on  established  and  novel  risk  factors  and  
vascular events in FMF are recommended.  
  New  opportunities  for  targeted  use  of  cardiovascular  
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inflammatory disorders may emerge with future prospective 
studies specifically looking at cardiovascular risk profiles in 
association with several inflammatory (IL-1beta, IL-6, IL-8, 
TNF-alpha,  IL-18)  and  genetic  markers  (the  MEFV  gene 
mutations).  
REFERENCES 
[1]  Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global 
and regional burden of disease and risk factors, 2001: systematic 
analysis of population health data. Lancet 2006; 367: 1747-57. 
[2]  Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-
74. 
[3]  Ikeda  U.  Inflammation  and  coronary  artery  disease.  Curr  Vasc 
Pharmacol 2003; 1: 65-70. 
[4]  Ferri C, Croce G, Cofini V, et al. C-reactive protein: interaction 
with the vascular endothelium and possible role in human athero-
sclerosis. Curr Pharm Des 2007; 13: 1631-45. 
[5]  Nakou ES, Liberopoulos EN, Milionis HJ, Elisaf MS. The role of 
C-reactive  protein  in  atherosclerotic  cardiovascular  disease:  an 
overview. Curr Vasc Pharmacol 2008; 6: 258-70. 
[6]  Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the 
site of inflammation: the leukocyte adhesion cascade updated. Nat 
Rev Immunol 2007; 7: 678-89. 
[7]  Schäfer  A,  Bauersachs  J.  Endothelial  dysfunction,  impaired  en-
dogenous platelet inhibition and platelet activation in diabetes and 
atherosclerosis. Curr Vasc Pharmacol 2008; 6: 52-60. 
[8]  McNicol A, Israels SJ. Beyond hemostasis: the role of platelets in 
inflammation,  malignancy  and  infection.  Cardiovasc  Hematol  
Disord Drug Targets 2008; 8: 99-117. 
[9]  Galkina E, Ley K. Immune and inflammatory mechanisms of athe-
rosclerosis (*). Annu Rev Immunol 2009; 27: 165-97. 
[10]  Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis  
in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-
47. 
[11]  Montecucco F, Mach F. Common inflammatory mediators orches-
trate pathophysiological processes in rheumatoid arthritis and athe-
rosclerosis. Rheumatology (Oxford) 2009; 48: 11-22. 
[12]  Kaplan MJ. Management of cardiovascular disease risk in chronic 
inflammatory disorders. Nat Rev Rheumatol 2009; 5: 208-17. 
[13]  Szekanecz  Z,  Koch  AE.  Vascular  involvement  in  rheumatic  
diseases: 'vascular rheumatology'. Arthritis Res Ther 2008; 10: 224. 
[14]  Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, 
Armstrong DJ. More than skin deep: atherosclerosis as a systemic 
manifestation of psoriasis. Br J Dermatol 2009; 161: 1-7. 
[15]  Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: 
disease-specific  and  non-disease-specific  risk  factors.  Semin 
Thromb Hemost 2009; 35: 313-24. 
[16]  Mathieu S, Joly H, Baron G, et al. Trend towards increased arterial 
stiffness  or  intima-media  thickness  in ankylosing  spondylitis  pa-
tients  without  clinically  evident  cardiovascular  disease.  Rheuma-
tology (Oxford) 2008; 47: 1203-7. 
[17]  Bilginer Y, Ozaltin F, Basaran C, et al. Evaluation of intima media 
thickness of the common and internal carotid arteries with inflam-
matory markers in familial Mediterranean fever as possible predic-
tors for atherosclerosis. Rheumatol Int 2008; 28: 1211-6. 
[18]  Gasparyan AY, Ugurlucan M. The emerging issue of cardiovascu-
lar  involvement  in  familial  Mediterranean  fever.  Arch  Med  Sci 
2008; 4: 465-7. 
[19]  Chae JJ, Aksentijevich I, Kastner DL. Advances in the understand-
ing of familial  Mediterranean fever and possibilities for targeted 























(T-, B-lymphocytes, monocytes, neutrophils, platelets)
It l k i 1 6 8 Tumor necrosis factor alpha 

Interleukins-1, -6, -8 Tumor necrosis factor alpha 
S li d A C reactive protein  Serum amyloidA 
Atherosclerotic burden  Endothelial dysfunction Platelet hyperactivation
Persistent subclinical inflammation
Increased cardiovascular riskFamilial Mediterranean Fever and Atherosclerosis  The Open Cardiovascular Medicine Journal, 2010, Volume 4    55 
[20]  Gattorno  M,  La  Regina  M,  Martini  A,  Manna  R. An  update  on 
autoinflammatory diseases. New concepts for new and old diseases. 
Clin Exp Rheumatol 2009; 27: 354-65. 
[21]  Fonnesu C, Cerquaglia C, Giovinale M, et al. Familial Mediterra-
nean Fever: a review for clinical management. Joint Bone Spine 
2009; 76: 227-33. 
[22]  Centola M, Wood G, Frucht DM, et al. The gene for familial Medi-
terranean fever, MEFV, is expressed in early leukocyte develop-
ment  and  is  regulated  in  response  to  inflammatory  mediators. 
Blood 2000; 95: 3223-31. 
[23]  Ozen S, Bakkaloglu A, Yilmaz E, et al. Mutations in the gene for 
familial Mediterranean fever: do they predispose to inflammation? 
J Rheumatol 2003; 30: 2014-8. 
[24]  Kalyoncu  M,  Acar  BC,  Cakar  N,  et  al.  Are  carriers  for  MEFV 
mutations "healthy"? Clin Exp Rheumatol 2006; 24 (5 Suppl 42): 
S120-2. 
[25]  Candore G, Balistreri CR, Grimaldi MP, et al. Opposite role of pro-
inflammatory alleles in acute myocardial infarction and longevity: 
results of studies performed in a Sicilian population. Ann NY Acad 
Sci 2006; 1067: 270-5. 
[26]  Giaglis S, Mimidis K, Papadopoulos V, et al. Increased frequency 
of mutations in the gene responsible for familial Mediterranean fe-
ver (MEFV) in a cohort of patients with ulcerative colitis: evidence 
for  a  potential  disease-modifying  effect?  Dig  Dis  Sci  2006;  51: 
687-92. 
[27]  Atagunduz  P,  Ergun  T,  Direskeneli  H.  MEFV  mutations  are  in-
creased in Behçet's disease (BD) and are associated with vascular 
involvement. Clin Exp Rheumatol 2003; 21 (4 Suppl 30): S35-7. 
[28]  Lachmann HJ, Sengül B, Yavuzşen TU, et al. Clinical and sub-
clinical inflammation in patients with familial Mediterranean fever 
and in heterozygous carriers of MEFV mutations. Rheumatology 
(Oxford) 2006; 45: 746-50. 
[29]  Korkmaz  C,  Ozdogan  H,  Kasapçopur  O,  Yazici  H. Acute phase 
response in familial Mediterranean fever. Ann Rheum Dis 2002; 
61: 79-81. 
[30]  Rozenbaum M, Naschitz JE, Yudashkin M, et al. Cardiovascular 
reactivity  score  for  the  assessment  of  dysautonomia  in  familial 
Mediterranean fever. Rheumatol Int 2004; 24: 147-52. 
[31]  Caliskan M, Gullu H, Yilmaz S, et al. Impaired coronary microvas-
cular  function  in  familial  Mediterranean  fever.  Atherosclerosis 
2007; 195: e161-7. 
[32]  Tavil Y, Ureten K, Oztürk MA, et al. The detailed assessment of 
left and right ventricular functions by tissue Doppler imaging in pa-
tients with familial Mediterranean fever. Clin Rheumatol 2008; 27: 
189-94. 
[33]  Hamuryudan V, Ozdoğan H, Yazici H. Other forms of vasculitis 
and pseudovasculitis. Baillieres Clin Rheumatol 1997; 11: 335-55. 
[34]  Serrano  R,  Martínez  MA,  Andrés  A,  Morales  JM,  Samartin  R. 
Familial mediterranean fever and acute myocardial infarction sec-
ondary to coronary vasculitis. Histopathology 1998; 33: 163-7. 
[35]  Cocco  G.  Vasculitis,  left  bundle  branch  block,  and  Raynaud’s 
phenomenon as a manisfestation of familial Mediterranean fever. 
Arch Med Sci 2008; 4: 460-4. 
[36]  Thurmon TF. Genetics, aging, and the heart. J La State Med Soc 
1998; 150: 356-66. 
[37]  Manna R, Cerquaglia C, Curigliano V, et al. Clinical features of 
familial  Mediterranean  fever:  an  Italian  overview. Eur  Rev  Med 
Pharmacol Sci 2009; 13(Suppl 1): 51-3. 
[38]  Lachmann  HJ,  Hawkins  PN.  Developments  in  the  scientific  and 
clinical understanding of autoinflammatory disorders. Arthritis Res 
Ther 2009; 11: 212. 
[39]  Yildiz A, Akkaya V, Kiliçaslan I, et al. Cardiac and intestinal amy-
loidosis in a renal transplant recipient with familial Mediterranean 
fever. J Nephrol 2001; 14: 125-7. 
[40]  Keven K, Oztas E, Aksoy H, Duman N, Erbay B, Ertürk S. Poly-
glandular endocrine failure in a patient with amyloidosis secondary 
to familial Mediterranean fever. Am J Kidney Dis 2001; 38: E39. 
[41]  Gasparyan  AY,  Petrosyan  AH.  Cardiac  involvement  in  familial 
Mediterranean  fever.  Cardiovas  Ther  Prevent  (Moscow)  2007; 6 
(6): 117-24. 
[42]  Muller WA.  Mechanisms of transendothelial migration of leuko-
cytes. Circ Res 2009; 105: 223-30. 
[43]  Wittchen ES. Endothelial signaling in paracellular and transcellular 
leukocyte transmigration. Front Biosci 2009; 14: 2522-45. 
[44]  Ungvári Z, Gupte SA, Recchia FA, Bátkai  S,  Pacher P. Role of 
oxidative-nitrosative  stress  and  downstream  pathways  in  various 
forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 
2005; 3: 221-9. 
[45]  Zalba G, Fortuño A, San José G, Moreno MU, Beloqui O, Díez J. 
Oxidative  stress,  endothelial  dysfunction  and  cerebrovascular  
disease. Cerebrovasc Dis 2007; 24(Suppl 1): 24-9. 
[46]  Direskeneli  H,  Ozdogan  H,  Korkmaz  C,  Akoglu  T,  Yazici  H.  
Serum soluble intercellular adhesion molecule 1 and interleukin 8 
levels  in  familial  Mediterranean  fever.  J  Rheumatol  1999;  26: 
1983-6. 
[47]  Haznedaroglu S, Oztürk MA, Sancak B, et al. Serum interleukin 17 
and interleukin 18 levels in familial Mediterranean fever. Clin Exp 
Rheumatol 2005; 23 (4 Suppl 38): S77-80. 
[48]  Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schön-
beck U. Expression of interleukin (IL)-18 and functional IL-18 re-
ceptor on human vascular endothelial cells, smooth muscle cells, 
and macrophages: implications for atherogenesis. J Exp Med 2002; 
195: 245-57. 
[49]  Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances 
atherosclerosis in apolipoprotein E(-/-) mice through release of in-
terferon-gamma. Circ Res 2002; 90: E34-8. 
[50]  Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclero-
sis:  a  comprehensive  review  of  studies  in mice. Cardiovasc  Res 
2008; 79: 360-76. 
[51]  Ozbalkan  Z,  Ozturk  MA,  Onat  AM,  et  al.  Circulating  thrombo-
modulin levels in familial Mediterranean fever. Clin Exp Rheuma-
tol 2006; 24 (5 Suppl 42): S95-8. 
[52]  Balat A, Işlek I, Cekmen M, et al. Adrenomedullin and total nitrite 
levels  in  children  with  familial  Mediterranean  fever.  J  Paediatr 
Child Health 2006; 42: 240-3. 
[53]  Terekeci HM, Oktenli C, Ozgurtas T, et al. Increased asymmetric 
dimethylarginine levels in young men with familial Mediterranean 
fever (FMF): is it early evidence of interaction between inflamma-
tion and endothelial dysfunction in FMF? J Rheumatol 2008; 35: 
2024-9. 
[54]  Gunesacar R, Erken E, Ozer HT, Bozkurt B, Dinkci S, Deveci D. 
Analysis  of  vascular  endothelial  growth  factor  gene  936  C/T  
polymorphism in patients with familial Mediterranean fever. Int J 
Immunogenet 2008; 35: 33-6. 
[55]  Başar  O,  Oztürk  MA,  Köklü  S,  et  al.  Plasma  levels  of  soluble  
vascular  endothelial  growth  factor  receptor-1  (sVEGFR-1)  in  
familial Mediterranean fever. Joint Bone Spine 2007; 74: 52-5. 
[56]  Aksu  G,  Ozturk  C,  Kavakli  K,  Genel  F,  Kutukculer  N.  Hyper- 
coagulability:  interaction  between  inflammation  and  coagulation  
in  familial  Mediterranean  fever.  Clin  Rheumatol  2007;  26:  366- 
70. 
[57]  Demirel A, Celkan T, Kasapcopur O, et al. Is Familial Mediterra-
nean Fever a thrombotic disease or not? Eur J Pediatr 2008; 167: 
279-85. 
[58]  Aoun EG, Musallam KM, Uthman I, Beydoun A, El-Hajj T, Taher 
AT.  Childhood  stroke  in  a  child  with  familial  Mediterranean  
fever carrying several prothrombotic risk factors. Lupus 2009; 18: 
845-7. 
[59]  Sari  S,  Egritas  O,  Bukulmez  A,  Dalgic  B,  Soylemezoglu  O.  Is 
familial  mediterranean  fever  a  possible  cofactor  for  budd-chiari 
syndrome? J Pediatr Gastroenterol Nutr 2009; 49(4): 481-4. 
[60]  Ozel Demiralp DF, Ekim M, Akar N. The effect of plasminogen 
activator  inhibitor-1  -675  4G/5G  polymorphism  on  Familial  
Mediterranean Fever (FMF) Disease. Clin Appl Thromb Hemost 
2009; 15(4): 443-7. 
[61]  Rabinovich E, Shinar Y, Leiba M, Ehrenfeld M, Langevitz P, Liv-
neh A. Common FMF alleles may predispose to development of 
Behcet's disease with increased risk for venous thrombosis. Scand J 
Rheumatol 2007; 36: 48-52. 
[62]  Coban  E,  Adanir  H.  Platelet  activation  in patients  with  Familial 
Mediterranean Fever. Platelets 2008; 19: 405-8. 
[63]  Makay B, Türkyilmaz Z, Unsal E. Mean platelet volume in chil-
dren with familial Mediterranean fever. Clin Rheumatol 2009; 28: 
975-8. 
[64]  Wagner DD, Burger PC. Platelets in inflammation and thrombosis. 
Arterioscler Thromb Vasc Biol 2003; 23: 2131-7. 
[65]  Smid J, Braun-Dullaeus R, Gawaz M, Langer HF. Platelet interac-
tions  as  therapeutic  targets  for  prevention  of  atherothrombosis.  
Future Cardiol 2009; 5: 285-96. 
[66]  Bots ML. Carotid intima-media thickness as a surrogate marker for 
cardiovascular disease in intervention studies. Curr Med Res Opin 
2006; 22: 2181-90. 56    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Yüksel et al. 
[67]  Gasparyan AY. The use of carotid artery ultrasonography in differ-
ent clinical conditions. Open Cardiovasc Med J 2009; 3: 78-80. 
[68]  Sari I, Karaoglu O, Can G, et al. Early ultrasonographic markers of 
atherosclerosis in patients with familial Mediterranean fever. Clin 
Rheumatol 2007; 26: 1467-73. 
[69]  Akdogan A, Calguneri M, Yavuz B, et al. Are familial Mediterra-
nean fever (FMF) patients at increased risk for atherosclerosis? Im-
paired endothelial function and increased intima media thickness 
are found in FMF. J Am Coll Cardiol 2006; 48: 2351-3. 
[70]  Peru  H,  Altun  B,  Doğan  M,  Kara  F,  Elmaci  AM, Oran  B.  The 
evaluation of carotid intima-media thickness in children with famil-
ial Mediterranean fever. Clin Rheumatol 2008; 27: 689-94. 
[71]  Ugurlu S, Seyahi E, Cetinkaya F, Ozbakir F, Balci H, Ozdogan H. 
Intima-media  thickening  in  patients  with  familial  Mediterranean 
fever. Rheumatology (Oxford) 2009; 48: 911-5. 
[72]  Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis 
Rheum 1998; 28: 48-59. 
[73]  Niel E, Scherrmann JM. Colchicine today. Joint Bone Spine 2006; 
73: 672-8. 
[74]  Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl 
J Med 1972; 287: 1302. 
[75]  Dinarello CA,  Wolff  SM, Goldfinger SE, Dale DC, Alling DW. 
Colchicine  therapy  for  familial  mediterranean  fever.  A  double-
blind trial. N Engl J Med 1974; 291: 934-7. 
[76]  Goldfinger  SE.  Familial  Mediterranean  fever--a  progress  report. 
West J Med 1977; 127: 40-1. 
[77]  Cerquaglia  C,  Diaco  M,  Nucera  G, La  Regina  M, Montalto  M, 
Manna R. Pharmacological and clinical basis of treatment of Famil-
ial Mediterranean Fever (FMF) with colchicine or analogues: an 
update. Curr Drug Targets Inflamm Allergy 2005; 4: 117-24. 
[78]  Ben-Chetrit E, Levy M. Does the lack of the P-glycoprotein efflux 
pump in neutrophils explain the efficacy of colchicine in familial 
Mediterranean  fever  and  other  inflammatory  diseases?  Med  
Hypotheses 1998; 51: 377-80. 
[79]  Abedat  S,  Urieli-Shoval  S,  Shapira  E,  Calko  S,  Ben-Chetrit  E, 
Matzner Y. Effect of colchicine and cytokines on MEFV expres-
sion  and  C5a  inhibitor activity  in human  primary  fibroblast cul-
tures. Isr Med Assoc J 2002; 4: 7-12. 
[80]  Ben-Chetrit  E,  Bergmann  S,  Sood  R.  Mechanism  of  the  anti-
inflammatory effect of colchicine in rheumatic diseases: a possible 
new outlook through microarray analysis. Rheumatology (Oxford) 
2006; 45: 274-82. 
[81]  Entzian P, Schlaak M, Seitzer U, Bufe A, Acil Y, Zabel P. Antiin-
flammatory and antifibrotic properties of colchicine: implications 
for idiopathic pulmonary fibrosis. Lung 1997; 175: 41-51. 
[82]  De  Socio  G,  Cerquaglia  C,  Curigliano  V,  et  al.  Association  
between familial mediterranean fever and retroperitoneal fibrosis: 
retroperitoneal  fibrosis  regression  after  colchicine  therapy.  Int  J 
Immunopathol Pharmacol 2009; 22: 521-4. 
[83]  Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice 
therapy for recurrent pericarditis: results of the CORE (COlchicine 
for REcurrent pericarditis) trial. Arch Intern Med 2005; 165: 1987-
91. 
[84]  Gasparyan AY. Effect of colchicine on ventricular diastolic reserve 
and pulmonary blood flow state in familial Mediterranean fever. J 
Arrhythmology (Saint-Petersburg) 2001; (24): 27-30. 
[85]  Langevitz P, Livneh A, Neumann L, et al. Prevalence of ischemic 
heart disease in patients with familial Mediterranean fever. Isr Med 
Assoc J 2001; 3: 9-12. 
[86]  Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) 
on  high-sensitivity  C-reactive  protein  independent of  aspirin  and 
atorvastatin in patients with stable coronary artery disease. Am J 
Cardiol 2007; 99: 805-7. 
[87]  Atta HM, El-Rehany MA, Abdel Raheim SR, Fouad R, Galal AM. 
Colchicine  inhibits  intimal  hyperplasia  and  leukocyte  VEGF  
expression in dogs. J Surg Res 2008; 146: 184-9.  
 
 
Received: November 06, 2009  Revised: November 20, 2009  Accepted: December 12, 2009 
 
© Yüksel et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ 
by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.  
 
 